	US 12,404,497 B2
	Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof
Fahar Merchant, Vancouver (CA)
Assigned to Medicenna Therapeutics Inc., Toronto (CA)
Appl. No. 15/733,815
Filed by Medicenna Therapeutics, Inc., Toronto (CA)
PCT Filed Jun. 3, 2019, PCT No. PCT/IB2019/000759 § 371(c)(1), (2) Date Nov. 30, 2020, PCT Pub. No. WO2019/239213, PCT Pub. Date Dec. 19, 2019.
Claims priority of provisional application 62/687,228, filed on Jun. 19, 2018.
Claims priority of provisional application 62/679,689, filed on Jun. 1, 2018.
Prior Publication US 2021/0238558 A1, Aug. 5, 2021
Int. Cl. C12N 15/861 (2006.01); A61K 35/766 (2015.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C12N 7/00 (2006.01); C12N 7/01 (2006.01); C12N 15/86 (2006.01)

CPC C12N 7/00 (2013.01) [A61K 35/766 (2013.01); C07K 14/544 (2013.01); C07K 14/55 (2013.01); C12N 15/86 (2013.01); C12N 2760/20232 (2013.01); C12N 2760/20243 (2013.01)]

11 Claims

1. A modified oncolytic virus vector comprising at least one nucleic acid sequence encoding an IL-4 receptor targeted cargo protein and an IL-2 mutein, wherein the oncolytic virus vector is a modified adenovirus vector.